Stocks Health care ATOS
NASDAQ · Health careAtossa Therapeutics, Inc. (ATOS)
It posted a net loss of $37.7M. In fiscal 2025 capital spending exceeded operating cash flow by $29.8M. At June 30, 2026 it held $26.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Atossa Therapeutics, Inc.
- Net worth
- Atossa Therapeutics, Inc. has a market value (market cap) of $20.3M at the latest share price, and shareholders' equity of $26.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $29.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Atossa Therapeutics, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
What Atossa Therapeutics, Inc. does
Atossa Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ATOS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$34.8M | -$4.04 | -$29.8M |
| 2024 | n/a | -$25.5M | -$3.04 | -$21M |
| 2023 | n/a | -$30.1M | -$3.65 | -$21M |
| 2022 | n/a | -$27M | -$3.19 | -$20.8M |
| 2021 | n/a | -$20.6M | -$2.74 | -$16.5M |
| 2020 | n/a | -$17.8M | -$29.94 | -$11.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Atossa Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Other event 8-K
- September 18, 2026
- August 7, 2026
- August 7, 2026
- June 11, 2026
- May 8, 2026Exhibits 8-K
- May 8, 2026
- May 8, 2026
- April 16, 2026Other event 8-K
- March 30, 2026
Insider trades
What the people running Atossa Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 12, 2026 | Cigler TessaDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Galli Stephen JDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Finn JonathanDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Remmel H. LawrenceDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Chen Shu-ChihDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Steinhart Richard IDirector | Received as pay | 10,000 | - |
| March 27, 2026 | Quay Steven CPresident & CEO, Director | Received as pay | 65,000 | - |
| March 26, 2026 | Daniel Mark JamesChief Financial Officer | Received as pay | 63,000 | - |
Who owns ATOS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
8 insiders reported holding 213,393 shares in total, about $433.2K at the last price.
| Holder | Shares |
|---|---|
| Quay Steven CPresident & CEO, Director | 88,038 |
| Daniel Mark JamesChief Financial Officer | 63,000 |
| Finn JonathanDirector | 11,666 |
| Remmel H. LawrenceDirector | 10,683 |
| Galli Stephen JDirector | 10,006 |
| Chen Shu-ChihDirector | 10,000 |
| Cigler TessaDirector | 10,000 |
| Steinhart Richard IDirector | 10,000 |
Questions about ATOS
What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ATOS. Its shares trade on NASDAQ under the ticker ATOS.
What is Atossa Therapeutics, Inc.'s net worth?
Atossa Therapeutics, Inc. has a market value (market cap) of $20.3M at the latest share price, and shareholders' equity of $26.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Atossa Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $37.7M.
When did Atossa Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 29, 2026.
When is Atossa Therapeutics, Inc.'s next earnings report?
Atossa Therapeutics, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
Similar companies
Compare ATOS with
Follow ATOS
Get an email when Atossa Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Atossa Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.